Details of the Drug Combinations

General Information of This Drug (ID: DMM7ZXR)

Drug Name
GSK2126458   DMM7ZXR
Synonyms
1086062-66-9; Omipalisib; GSK-2126458; GSK 2126458; UNII-1X8F5A3NA0; 2,4-difluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide; 2,4-difluoro-N-[2-methoxy-5-(4-pyridazin-4-ylquinolin-6-yl)pyridin-3-yl]benzenesulfonamide; 2,4-Difluoro-N-[2-methoxy-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl]benzenesulfonamide; 1X8F5A3NA0; Omipalisib (GSK2126458, GSK458); C25H17F2N5O3S; Omipalisib [USAN:INN]
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 1 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

60 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
ABT-263 + GSK2126458 DCK1U54 ABT-263 Glioblastoma (Cell Line: JHH-136) [2]
Alvespimycin hydrochloride + GSK2126458 DC9LAY6 Alvespimycin hydrochloride Hepatoblastoma (Cell Line: HB3) [2]
AS602868 + GSK2126458 DCY873U AS602868 Glioblastoma (Cell Line: JHH-136) [3]
AZD8055 + GSK2126458 DCQB2T5 AZD8055 Glioblastoma (Cell Line: JHH-136) [3]
Bardoxolone methyl + GSK2126458 DC0YNDH Bardoxolone methyl Glioblastoma (Cell Line: JHH-136) [3]
BGJ398 + GSK2126458 DCBMDSR BGJ398 Embryonal rhabdomyosarcoma (Cell Line: Rh36) [2]
BGJ398 + GSK2126458 DCXKGXA BGJ398 Embryonal rhabdomyosarcoma (Cell Line: CTR) [2]
BGJ398 + GSK2126458 DCH0RAL BGJ398 Embryonal rhabdomyosarcoma (Cell Line: RD) [2]
BIIB-021 + GSK2126458 DC6SOH9 BIIB-021 Glioblastoma (Cell Line: JHH-136) [3]
Calindol + GSK2126458 DC06BXJ Calindol DD2 (Cell Line: DD2) [3]
Cladribine + GSK2126458 DCBZFIH Cladribine Glioblastoma (Cell Line: JHH-136) [3]
Emetine + GSK2126458 DC2ATV7 Emetine DD2 (Cell Line: DD2) [3]
Everolimus + GSK2126458 DC9DUE4 Everolimus Embryonal rhabdomyosarcoma (Cell Line: Rh36) [3]
Everolimus + GSK2126458 DCXQL0V Everolimus Embryonal rhabdomyosarcoma (Cell Line: CTR) [3]
Gentian violet + GSK2126458 DCLUPPZ Gentian violet Hepatoblastoma (Cell Line: HB3) [2]
GSK2126458 + Clindamycin DCUEU55 Clindamycin DD2 (Cell Line: DD2) [3]
GSK2126458 + Ruxolitinib DCQWOC7 Ruxolitinib T-cell leukemia/lymphoma (Cell Line: ED-40515) [3]
GSK2126458 + Trametinib DCBOW13 Trametinib Glioblastoma (Cell Line: JHH-136) [3]
GSK2126458 + Carfilzomib DCC7ULR Carfilzomib Glioblastoma (Cell Line: JHH-136) [3]
GSK2126458 + Panobinostat DCTUNFF Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
GSK2126458 + Ixazomib DCKI5E0 Ixazomib Glioblastoma (Cell Line: JHH-136) [3]
GSK2126458 + Naltrexone DC3M2SQ Naltrexone DD2 (Cell Line: DD2) [3]
GSK2126458 + Quinine DC9LBBC Quinine DD2 (Cell Line: DD2) [3]
GSK2126458 + Piperaquine DC1GL5L Piperaquine DD2 (Cell Line: DD2) [3]
GSK2126458 + Pyronaridine DC07KHS Pyronaridine DD2 (Cell Line: DD2) [3]
GSK2126458 + Mefloquine DCK0ZTL Mefloquine DD2 (Cell Line: DD2) [3]
GSK2126458 + Clindamycin DC4X3OG Clindamycin Hepatoblastoma (Cell Line: HB3) [2]
GSK2126458 + Trametinib DCWCEJE Trametinib Embryonal rhabdomyosarcoma (Cell Line: CTR) [2]
GSK2126458 + Trametinib DCVCXRI Trametinib Embryonal rhabdomyosarcoma (Cell Line: RD) [2]
GSK2126458 + JQ1 DCBPIX1 JQ1 Embryonal rhabdomyosarcoma (Cell Line: Rh36) [2]
GSK2126458 + JQ1 DCA1K6M JQ1 Embryonal rhabdomyosarcoma (Cell Line: RD) [2]
GSK2126458 + Belinostat DCJ7Z8D Belinostat Embryonal rhabdomyosarcoma (Cell Line: Rh36) [2]
GSK2126458 + Doxycycline DCGSU4W Doxycycline Hepatoblastoma (Cell Line: HB3) [2]
GSK2126458 + PMID25656651-Compound-5 DCIH7OL PMID25656651-Compound-5 Embryonal rhabdomyosarcoma (Cell Line: Rh36) [2]
GSK2126458 + PMID25656651-Compound-5 DCSWZ68 PMID25656651-Compound-5 Embryonal rhabdomyosarcoma (Cell Line: CTR) [2]
GSK2126458 + PMID25656651-Compound-5 DCWBAGS PMID25656651-Compound-5 Embryonal rhabdomyosarcoma (Cell Line: RD) [2]
GSK2126458 + Ceritinib DCMISIV Ceritinib Embryonal rhabdomyosarcoma (Cell Line: Rh36) [2]
GSK2126458 + Ceritinib DCSNPVP Ceritinib Embryonal rhabdomyosarcoma (Cell Line: CTR) [2]
GSK2126458 + Ceritinib DCFD6FY Ceritinib Embryonal rhabdomyosarcoma (Cell Line: RD) [2]
GSK2126458 + Methylene blue DC7L795 Methylene blue Hepatoblastoma (Cell Line: HB3) [2]
GSK2126458 + Artemisinin DC7SWX8 Artemisinin Hepatoblastoma (Cell Line: HB3) [2]
GSK2126458 + BMS-754807 DCCUU9L BMS-754807 Embryonal rhabdomyosarcoma (Cell Line: Rh36) [2]
GSK2126458 + BMS-754807 DCSW4ID BMS-754807 Embryonal rhabdomyosarcoma (Cell Line: CTR) [2]
GSK2126458 + BMS-754807 DC7XIF3 BMS-754807 Embryonal rhabdomyosarcoma (Cell Line: RD) [2]
GSK2126458 + Chloroquine DC1XHHN Chloroquine Hepatoblastoma (Cell Line: HB3) [2]
GSK2126458 + Quinine DCC0WVC Quinine Hepatoblastoma (Cell Line: HB3) [2]
KN-62 + GSK2126458 DCZDILF KN-62 DD2 (Cell Line: DD2) [3]
KN-62 + GSK2126458 DCMT928 KN-62 Hepatoblastoma (Cell Line: HB3) [2]
Mefloquine + GSK2126458 DCXDW60 Mefloquine DD2 (Cell Line: DD2) [3]
PAC1 + GSK2126458 DC0OKG0 PAC1 Glioblastoma (Cell Line: JHH-136) [3]
Panobinostat + GSK2126458 DCBG7C5 Panobinostat DD2 (Cell Line: DD2) [3]
PD-0173955 + GSK2126458 DCMMTIG PD-0173955 Hepatoblastoma (Cell Line: HB3) [2]
Pelitinib + GSK2126458 DCCQHDB Pelitinib Glioblastoma (Cell Line: JHH-136) [3]
Relugolix + GSK2126458 DC3QS01 Relugolix DD2 (Cell Line: DD2) [3]
SCH772984 + GSK2126458 DCBXNDC SCH772984 Embryonal rhabdomyosarcoma (Cell Line: Rh36) [2]
SCH772984 + GSK2126458 DCH0KG2 SCH772984 Embryonal rhabdomyosarcoma (Cell Line: CTR) [2]
SCH772984 + GSK2126458 DCDGF1E SCH772984 Embryonal rhabdomyosarcoma (Cell Line: RD) [2]
Sitosterol + GSK2126458 DCQIJRH Sitosterol DD2 (Cell Line: DD2) [3]
TAK-733 + GSK2126458 DC9QHDA TAK-733 Glioblastoma (Cell Line: JHH-136) [3]
Topetecan + GSK2126458 DCT9J6N Topetecan Glioblastoma (Cell Line: JHH-136) [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 60 DrugCom(s)

References

1 Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma. Mol Cancer Ther. 2015 Feb;14(2):429-39.
2 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.